Core Healthcare Group

1. GlaxoSmithKline, LLC. $500,877 34 payments
2. Taro Pharmaceuticals USA, Inc. $232,110 19 payments
3. Journey Medical Corporation $130,628 6 payments
4. Amgen Inc. $70,805 8 payments
5. AstraZeneca Pharmaceuticals LP $40,755 2 payments
6. Dexcom, Inc. $5,628 11 payments
7. GRT US Holding, Inc. $840 12 payments
8. Pfizer Inc. $192 4 payments

1. A Multicentre Randomized, Double-Blind, Placebo-Controlled, Dose-Findi $384,648 21 payments
2. Dfd-29-Cd-004 $130,628 6 payments
3. A Multicenter Randomized, Double-Blind, Placebo-Controlled Phase 2 Stu $116,229 13 payments
4. Ivrc 2002 $109,065 9 payments
5. Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris $57,952 4 payments
6. A Randomized, Double-Blind, Multiple Center Placebo Controlled Study Comparing Taro Product to RLD and Both Treatments to a Placebo Control in the Treatment of Acne Vulgaris $52,358 4 payments
7. A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight (MARITIME-2) $47,417 2 payments
8. A Phase IIb Randomised, Double-blind, Placebocontrolled Study to Evaluate the Efficacy, Safety and Tolerability of Coadministration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND) $37,761 1 payment
9. Medication Overuse Headache Study (MOH)_ $21,353 3 payments
10. Study $11,880 1 payment

1. Professional salary support $213,980 16 payments
2. Patient care $15,143 2 payments
3. Overhead $6,250 2 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.